CAR T-Cells in the Treatment Landscape of Mantle Cell Lymphoma – Targeted Oncology
Targeted Oncology |
CAR T-Cells in the Treatment Landscape of Mantle Cell Lymphoma
Targeted Oncology Owen O’Connor, MD, PhD, director of the Center for Lymphoid Malignancies at New York-Presbyterian Hospital, discusses the possibility of using chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with mantle cell lymphoma (MCL … |
Targeted Oncology |
CAR T-Cells in the Treatment Landscape of Mantle Cell Lymphoma
Targeted Oncology Owen O’Connor, MD, PhD, director of the Center for Lymphoid Malignancies at New York-Presbyterian Hospital, discusses the possibility of using chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with mantle cell lymphoma (MCL … |
Labiotech.eu (blog) |
Bluebird Bio’s Gets Positive Results For Beta-Thalassemia Gene …
Labiotech.eu (blog) bluebird bio, a Swiss-US firm, has obtained interim data from two clinical studies showing its new gene therapy could eliminate the need for red blood cell transfusions in patients with beta-thalassemia. Gene Therapy for Thalassemia Shows PromiseNorthwestern University NewsCenter A Gene Therapy, Successful In Beta-Thalassemia, Might Lead To …Health Thoroughfare Bluebird Bio One Step Closer to First Approved DrugPharmaLive (press release) Motley Fool –Brinkwire (press release) all 7 news articles » |
